Eradication of established tumors by CD8+ T cell adoptive immunotherapy.

[1]  D. Kioussis,et al.  Tumor size at the time of adoptive transfer determines whether tumor rejection occurs , 2000, European journal of immunology.

[2]  D. Linehan,et al.  Immunotherapeutic approaches to sarcoma. , 1999, Seminars in surgical oncology.

[3]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[4]  Lunli Yuan,et al.  Adoptive immunotherapy prevents prostate cancer in a transgenic animal model , 1999, European journal of immunology.

[5]  B. Moss,et al.  Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  P. Klenerman,et al.  Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  B. Robinson,et al.  T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. , 1999, Cancer research.

[8]  P. Shrikant,et al.  Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. , 1999, Journal of immunology.

[9]  Yang Liu,et al.  Cytotoxic T Lymphocytes to An Unmutated Tumor Rejection Antigen P1A: Normal Development but Restrained Effector Function In Vivo , 1999, The Journal of experimental medicine.

[10]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[11]  H. Pircher,et al.  Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. , 1998, Journal of immunology.

[12]  B. Moss,et al.  gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.

[13]  P. Allen,et al.  TCR Transgenic Mice in Which Usage of Transgenic α- and β-Chains Is Highly Dependent on the Level of Selecting Ligand , 1998, The Journal of Immunology.

[14]  R. Offringa,et al.  Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. , 1998, Journal of immunology.

[15]  D. Pardoll,et al.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Fleuren,et al.  Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes , 1997, The Journal of experimental medicine.

[17]  J. Bluestone,et al.  Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy , 1997, The Journal of experimental medicine.

[18]  H. Ikeda,et al.  Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Allen,et al.  TCR recognition of the Hb(64-76)/I-Ek determinant: single conservative amino acid changes in the complementarity-determining region 3 dramatically alter antigen fine specificity. , 1996, Journal of immunology.

[20]  R. Offringa,et al.  Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. , 1996, Journal of immunology.

[21]  K. Zier,et al.  Molecular basis of T cell dysfunction in cancer is influenced by the paracrine secretion of tumor-derived IL-2. , 1996, Journal of immunology.

[22]  David Gray,et al.  Immunological Memory and Protective Immunity: Understanding Their Relation , 1996, Science.

[23]  J. Allison,et al.  Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. , 1996, Journal of immunology.

[24]  L. Zitvogel,et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.

[25]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[26]  J. Renauld,et al.  Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. , 1995, Journal of immunology.

[27]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[28]  S. Rosenberg,et al.  Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. , 1994, Cancer research.

[29]  D. Loh,et al.  Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. , 1994, Immunity.

[30]  M P Cooke,et al.  Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4+ T cells , 1994, The Journal of experimental medicine.

[31]  E. Gilboa,et al.  The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. , 1994, Journal of immunology.

[32]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[33]  M. Matsuda,et al.  Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. , 1993, Cancer research.

[34]  P. Greenberg,et al.  An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues , 1993, The Journal of experimental medicine.

[35]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Longo,et al.  Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. , 1992, Science.

[37]  M. Bevan,et al.  Dissection of major histocompatibility complex (MHC) and T cell receptor contact residues in a Kb‐restricted ovalbumin peptide and an assessment of the predictive power of MHC‐binding motifs , 1992, European journal of immunology.

[38]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[39]  Hans-Georg Rammensee,et al.  Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells , 1990, Nature.

[40]  E. Gilboa,et al.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.

[41]  W. Lie,et al.  Peptide ligand-induced conformation and surface expression of the Ld class I MHC molecule , 1990, Nature.

[42]  P. Srivastava,et al.  Tumor rejection antigens of chemically induced sarcomas of inbred mice. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Custer,et al.  Severe combined immunodeficiency (SCID) in the mouse. Pathology, reconstitution, neoplasms. , 1985, The American journal of pathology.

[44]  T. Eberlein,et al.  Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations. , 1984, Journal of immunology.

[45]  L. Old,et al.  Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma , 1977, The Journal of experimental medicine.

[46]  L. Old,et al.  ANTIGENIC PROPERTIES OF CHEMICALLY INDUCED TUMORS * , 1962 .